Skip to main content
Gene Editing Services hero - blue

StemEdit
Next-Level Gene Editing Service

AI-Designed Gene Editing for Research,
Cell Therapy Development & Clinical Translation

StemEdit Service Overview

StemEdit provides end-to-end genome editing services for mammalian cells, with specialized expertise in iPSCs, supporting programs from research through clinical translation.

Combining AI-designed genome editing, engineered cell lines, and custom editing services, StemEdit enables researchers to accelerate discovery, engineer complex cell models, and advance translational and cell therapy programs without complex licensing requirements.

For stem cell applications, StemEdit enables a seamless transition from research-grade editing to clinical-grade iPSC lines without restarting cell line development.

StemEdit service overview 2

As part of the StemEdit platform, OC-1 complements REPROCELL's knockout cell lines, landing pad technology, and custom gene editing services to provide a comprehensive genome engineering solution. 

Why Choose StemEdit?

AI-Designed Precision Editing

StemEdit is powered by OC-1, REPROCELL's AI-designed gene editing nuclease based on OpenCRISPR™-1. Integrated into our StemEdit Gene Editing Service, OC-1 enables high-precision, high-efficiency genome editing with reduced off-target activity. Optimized for high-performance genome editing in human cells, OC-1 combines precision, and efficiency, and a license-free model to supporting stem cell engineering and translational research. REPROCELL scientists apply this technology to deliver custom genome editing for stem cell engineering, translational research, and cell therapy development.

For researchers who prefer to perform genome editing in-house, StemEdit OC-1 Protein is also available as a purified, ready-to-use nuclease for research use in your own laboratory.

Core Advantages of StemEdit

  • License-Included: Gene Editing Service & Hypoimmune Cell Lines
    Freedom to operate without licensing restrictions, accelerating research and commercialization.

  • Precision & Safety
    AI-designed nuclease delivers high editing efficiency, reduced off-target activity, and lower predicted immunogenicity.

  • Accelerated Development
    Minimize iterative editing and clone screening to shorten development timelines.

  • Clinical Alignment
    Generate precisely defined genotypes in research-grade cells before transferring seamlessly to matched clinical-grade iPSC seed banks for GMP manufacturing.

Integrated Licensing for StemEdit Services & Hypoimmune iPSCs

 License included
Research • Clinical • Commercial

For StemEdit Gene Editing Services and Hypoimmune iPSC lines, the applicable license for research, clinical, and commercial use is included with the product or service. No separate or additional license for the StemEdit gene editing platform is required, subject to the applicable terms of use and service agreement.

Using OC-1 in your own laboratory?
StemEdit OC-1 Protein is available separately in Research and GMP formats for in-house use. Commercial use requires a separate commercial-use agreement with Profluent Bio. Please contact REPROCELL for further information.

Please note: Users remain responsible for ensuring compliance with applicable third-party intellectual property covering guide RNAs, delivery methods, and downstream applications.

StemEdit Capabilities

StemEdit provides tailored genome editing services to generate the precise genetic modifications your project requires. Programs can begin with research-grade editing and screening, and transition seamlessly to clinical-grade iPSC development using aligned processes and documentation. StemEdit enables a wide range of complex genetic modifications in iPSCs with reproducibility and traceability. 

  • Knock-in of large gene fragments (e.g., reporters, regulatory elements via landing pad technology)
  • Knock-in of biallelic mutations for disease models or functional studies
  • Knock-out of single or multiple genes

 
From research to clinical development:

Discover how StemEdit combines AI-designed genome editing with matched research and clinical-grade iPSC workflows to streamline the path from discovery to translational development. 

Flexible Starting Material

StemEdit is designed to fit your program:

  • Use your own iPSC line
  • Select from REPROCELL’s research- and clinical-grade iPSC clones
  • Request custom iPSC line generation tailored to your project needs, from disease models to therapeutic candidates

Flexible Facility Options — USA & Japan

You can run your StemEdit project at either:

Choose the site that aligns with your timeline, throughput, and regulatory requirements.

StemEdit - REPROCELL USA and Japan

References

  1. Ruffolo JA, Nayfach S, Gallagher J, et al.Design of highly functional genome editors by modelling CRISPR-Cas sequences. Nature 645(8080):518-525, (2025).
  2. Thomson T, Li G, Strilchuk A, et al. Harnessing artificial intelligence to advance CRISPR-based genome editing technologies. Nature Reviews Genetics 27, pages 212–230, (2026).

Contact our experts